Core Insights - Scinai Bioservices, a CDMO unit launched by Scinai in 2024, operates from a facility in Jerusalem, Israel, featuring 1,850 square meters of clean rooms and laboratories compliant with cGMP standards [2][3] - The CDMO unit has engaged in drug development projects for various biotech companies, including upstream and downstream process development, scale-up, and drug manufacturing for clinical trials [3] - Scinai's U.S. subsidiary, Scinai Bioservices Inc., aims to support early-stage biotech companies in the U.S. by providing essential CDMO services that are currently in short supply [4] Company Overview - Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) operates two business units: one focused on developing biological therapeutic products for inflammation and immunology, and the other providing CDMO services to early-stage biotech companies [5] - The company is actively seeking partnerships with potential pharma partners in the fields of inflammation and immunology, as well as institutional and private investors interested in its value proposition [7]
Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025